CTAD 2026: Biogen and AriBio report signals of slower cognitive decline

At CTAD 2026, Biogen reported two-year results from its Phase 2 CELIA study of diranersen, an investigational anti-tau therapy. The 60 mg twice-yearly group showed a reported 38% slowing of decline on the CDR-SB measure at Week 96, compared with 26% at 18 months. These were numerical results:
the study missed its primary endpoint, so they are not proof of efficacy.

AriBio reported Phase 3 POLARIS-AD results for AR1001, an oral investigational drug. In a prespecified subgroup of 604 participants not taking other Alzheimer’s medicines, decline was 31% slower than with placebo over 52 weeks. In the overall 1,535-person trial, the difference was smaller—7%—and not statistically significant.

The findings are encouraging but preliminary and differ in strength:
AriBio’s positive result was confined to a subgroup, while Biogen’s reported longer-term benefit came from a Phase 2 study that missed its primary endpoint. Neither report establishes that these drugs slow Alzheimer’s decline for the broader patient population.

Safety reports noted more diarrhea with AR1001 than placebo (7.7% versus 4.4%); adverse-event-related discontinuations were also higher (5.2% versus 1.7%). Biogen reported no new safety signals in the two-year diranersen data.

AriBio said it plans to discuss AR1001’s results with the FDA. Both candidates remain investigational; the reported percentages describe differences in measured decline versus placebo, not improvement or reversal of Alzheimer’s symptoms.

Sources:

19th Clinical Trials on Alzheimer’s Disease (CTAD) conference

19th Clinical Trials on Alzheimer's Disease (CTAD) conference (Boston, ...

Clinical Trials on Alzheimer's Disease: Home

2026

CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in ...

Cognition Therapeutics Announces CTAD Poster Highlighting ...

CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive ...

Eisai to Present New Five-Year Lecanemab Data and Real ...

Acadia Pharmaceuticals to Present Remlifanserin Data at the ...

Circular Genomics to Present Five Abstracts and Participate in Key Industry Initiatives at Clinical Trials on Alzheimer's Disease (CTAD) 2026

Alzheimer's field looks beyond amyloid as biopharma converges at ...

PRELIMINARY PROGRAM CTAD 2026

Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two ...

Alamar Biosciences Highlights NULISA Data in 46 ...

New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer's, Says the ADDF